1
|
Ben Thabet J, Gassara I, Smaoui N, Msaad S, Maalej Bouali M, Yaich S, Omri S, Feki R, Zouari L, Charfi N, Maalej M. [Effects of continuous positive airway pressure on depression, anxiety and quality of life in obstructive sleep apnea hypopnea syndrome patients]. Encephale 2021; 48:397-403. [PMID: 34311963 DOI: 10.1016/j.encep.2021.04.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 04/15/2021] [Accepted: 04/30/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The obstructive sleep apnea hypopnea syndrome (OSAHS) is a chronic stressor that may alter the emotional state and quality of life (QOL) of patients suffering from it. In this work, we proposed to estimate the prevalence of depression and anxiety, to assess the QOL in a Tunisian population of apneic patients, and to assess their evolution under continuous positive airway pressure (CPAP). METHODS We conducted a prospective study, involving 33 apneic patients followed for SAHOS with moderate or severe class disease in the pneumology department at Hedi Chaker university hospital in Sfax, Tunisia. They received CPAP treatment for three months. We used an epidemiological record. Two scales, the Hospital Anxiety and Depression Scale (HADS) and the 36-item Short-Form Health Survey (SF-36), were completed before and after treatment to evaluate the effect of three months of treatment with CPAP. RESULTS The prevalence of depression in the study's patients, according to the HADS, was 45.5% and that of anxiety was 21.2%. After 3months of CPAP, the prevalence of depression and anxiety had become 18.2% and 6.1%, respectively. QOL was impaired in 81.8% of cases before treatment, according to the SF-36. This figure had decreased to 69.7% after 3months of treatment with CPAP. Apart from the third dimension (physical pain), all other dimensions were significantly improved after 3months of CPAP treatment. The treatment with CPAP induced a significant improvement in the average scores of depression (P<0.001), anxiety (P=0.002) and QOL (P<0.001). CONCLUSIONS These results attest to the importance of the frequency of anxio-depressive disorders as well as an altered QOL in patients with OSAHS. CPAP treatment was shown to be effective in improving these parameters, but this efficacy was partial. Specialized care may be needed in cases of residual anxio-depressive symptoms.
Collapse
Affiliation(s)
- J Ben Thabet
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - I Gassara
- Service de psychiatrie légale, hôpital Razi, Mannouba, Tunis, Tunisie
| | - N Smaoui
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.
| | - S Msaad
- Service de pneumologie, CHU Hédi Chaker, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - M Maalej Bouali
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - S Yaich
- Service de médecine préventive, CHU Hédi Chaker, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - S Omri
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - R Feki
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - L Zouari
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - N Charfi
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| | - M Maalej
- Service de psychiatrie « C », CHU Hédi Chaker, route Elain km 0,5, 3029 Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie
| |
Collapse
|
2
|
Lerousseau L. [Sleepiness, continuous positive airway pressure and the obstructive sleep apnea hypopnea syndrome]. Rev Mal Respir 2018; 35:116-33. [PMID: 29454715 DOI: 10.1016/j.rmr.2017.04.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 04/01/2017] [Indexed: 12/23/2022]
Abstract
Excessive daytime sleepiness is a major symptom in cases of the obstructive sleep apnea-hypopnea syndrome. Most often, it is vastly improved by treatment with continuous positive airway pressure (CPAP). The most effective way to confirm its disappearance is through wakefulness maintenance testing. If residual sleepiness remains, despite CPAP, further diagnostic investigation must be carried out. Firstly, it must be assessed whether the treatment is fully effective (apnea hypopnea index<10/h) by examining flow limitations under treatment (polysomnography) and whether it is sufficiently used (>6h/night). If this is the case, the possibility of other situations responsible for excessive daytime sleepiness must be reviewed and eliminated, whether they are depression, sleep insufficiency, use of intoxicants, obesity, restless legs syndrome, or circadian sleep-wake cycle disorder. If not, the multiple sleep latency tests make it possible to assess sleepiness (latency<8min) and can lead to a diagnosis of central hypersomnia (narcolepsy, idiopathic hypersomnia, hypersomnia due to a medical pathology). In some rare cases (about 6% of patients) investigations will reveal central hypersomnia due to the obstructive sleep apnea-hypopnea syndrome or "lesional" hypersomnia due to intermittent hypoxia. Since 2011, medications treating excessive sleepiness have had marketing authorization only for narcolepsy in France. However, they can be administered by way of derogation to other neurological hypersomnias on prescription by a reference centre or a centre with expertise in hypersomnia.
Collapse
|